Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / IL6



This biomarker is also known as:
  • CDF,
  • B-cell stimulatory factor 2,
  • interleukin 6 (interferon, beta 2),
  • BSF-2,
  • CTL differentiation factor,
  • Interferon beta-2,
  • IFN-beta-2,
  • Interleukin 6,
  • B cell stimulatory factor-2,
  • IFNB2,
  • B-cell differentiation factor,
  • BSF2,
  • IL-6,
  • Hybridoma growth factor,
  • HSF,
  • HGF,

View in BioMuta


Interleukin 6 (IL6) is a cytokine that is involved in inflammation and the maturation of B cells as well as induction of the acute phase response. In addition to inducing myeloma and plasmacytoma growth and nerve cell differentiation, it also plays an important role in the differentiation of B-cells into Ig-secreting cells involved in lymphocyte and monocyte differentiation. The IL6 protein is produced mainly at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The IL6 gene is involved in many inflammation-associated disease states, including diabetes mellitus, where it acts on insulin resistance, and systemic juvenile rheumatoid arthritis. IL6 is discharged into the bloodstream after muscle contraction.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: IL6


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


IL6 alone is not a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.